logo
Plus   Neg
Share
Email

Zogenix Shares Down 32% After FDA Refuses To Review Seizure Drug

Shares of Zogenix Inc. (ZGNX) plunged 32% in the extended session Monday after the company said the Food and Drug Administration did not accept a marketing application for one of its drugs.

Zogenix, a pharmaceutical company developing rare disease therapies, said it received a Refusal to File letter from FDA regarding its New Drug Application for Fintepla for the treatment of seizures associated with Dravet syndrome.

The FDA determined that the application was not sufficiently complete to permit a substantive review. FDA cited two reasons for the RTF decision: first, certain non-clinical studies were not submitted to allow assessment of the chronic administration of fenfluramine; and, second, the application contained an incorrect version of a clinical dataset, which prevented the completion of the review process that is necessary to support the filing of the NDA.

"We remain highly confident in FINTEPLA's clinical profile demonstrated in the Phase 3 program in Dravet syndrome and are committed to advancing the product candidate as a potential new treatment option for this and other rare and often catastrophic epileptic encephalopathies," said Stephen J. Farr, Ph.D., President and CEO of Zogenix. "We are fully committed to working with the FDA as quickly as possible to address the open issues and clarify the path to successfully re-filing our application."

ZGNX closed Monday's trading at $51.85, down $0.15 or 0.29% on the Nasdaq. The stock further dropped $16.59 or 32% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT